Caffeine potentiates methamphetamine-induced toxicity both in vitro and in vivo

Neuroscience Letters

Volumn 502, Issue 1, 2011, Pages 65-69

  Sinchai, Theerin ^a   Plasen, Surin ^a   Sanvarinda, Yupin ^a   Jaisin, Yamaratee ^b   Govitrapong, Piyarat ^a,c   Morales, Noppawan Phumala ^a   Ratanachamnong, Piyanee ^a   Plasen, Duangporn ^b  

^a Mahidol University   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Bax Bcl 2 ratio; Caffeine; Methamphetamine; TBARS; Ya Ba

Indexed keywords

CAFFEINE; METHAMPHETAMINE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MORTALITY; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CAFFEINE; CELL LINE, TUMOR; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DRUG SYNERGISM; MALE; METHAMPHETAMINE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 80051787120     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.07.026     Document Type: Article

References (26)

1. Albers D.S., Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 1995, 275:1104-1114.
2. Borycz J., Pereira M.F., Melani A., Rodrigues R.J., Köfalvi A., Panlilio L., Pedata F., Goldberg S.R., Cunha R.A., Ferré S. Differential glutamate dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J. Neurochem. 2007, 101:355-363.
3. Cadet J.L., Krasnova I.N. Molecular bases of methamphetamine-induced neurodegeneration. Int. Rev. Neurobiol. 2009, 88:101-119.
4. CCAC, Guide to the Care and Used of Experimental Animals, Published by the Canadian Council on Animal Care, vol. 1, 1993. http://www.ccac.ca/.
5. Cui M., Aras R., Christian W.V., Rappold P.M., Hatwar M., Panza J., Jackson-Lewis V., Javitch J.A., Ballatori N., Przedborski S., Tieu K. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8043-8048.
6. Darke S., Kaye S., McKetin R., Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008, 27:253-262.
7. Delle Donne K.T., Sonsalla P.K. Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther. 1994, 271:1320-1326.
8. Derlet R.W., Tseng J.C., Albertson T.E. Potentiation of cocaine and d-amphetamine toxicity with caffeine. Am. J. Emerg. Med. 1992, 10:211-216.
9. Guilarte T.R. Is methamphetamine abuse a risk factor in Parkinsonism?. Neurotoxicology 2001, 22:725-731.
10. Golembiowska K., Dziubina A., Kowalska M., Kaminska K. Effect of adenosine A2A receptor antagonists on l-DOPA-induced hydroxyl radical formation in rat striatum. Neurotox. Res. 2009, 15:155-166.
11. Ikeda R., Igari Y., Fuchigami Y., Wada M., Kuroda N., Nakashima K. Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain. Eur. J. Pharmacol. 2011, 660:318-325.
12. Karatzis E., Papaioannou T.G., Aznaouridis K., Karatzi K., Stamatelopoulos K., Zampelas A., Papamichael C., Lekakis J., Mavrikakis M. Acute effects of caffeine on blood pressure and wave reflections in healthy subjects: should we consider monitoring central blood pressure?. Int. J. Cardiol. 2005, 98:425-430.
13. Kulsudjarit K. Drug problem in southeast and southwest Asia. Ann. N. Y. Acad. Sci. 2004, 1025:446-457.
14. Kuribara H. Caffeine enhances the stimulant effect of methamphetamine, but may not affect induction of methamphetamine sensitization of ambulation in mice. Psychopharmacology 1994, 116:125-129.
15. Lee C. Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation. Clin. Chim. Acta 2000, 295:141-154.
16. Mau M.K., Asao K., Efird J., Saito E., Ratner R., Hafi M., Seto T. Risk factors associated with methamphetamine use and heart failure among native Hawaiians and other Pacific Island peoples. Vasc. Health Risk Manag. 2009, 5:45-52.
17. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Fukuda M., Kitaichi K., Miyoshi K., Ogawa N. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J. 2006, 20:571-573.
18. Okada M., Kiryu K., Kawata Y., Mizuno K., Wada K., Tasaki H., Kaneko S. Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur. J. Pharmacol. 1997, 321:181-188.
19. Popoli P., Reggio R., Pèzzola A., Fuxe K., Ferré S. Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neurosci. Lett. 1998, 251:201-204.
20. Pubill D., Chipana C., Camins A., Pallás M., Camarasa J., Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol. Appl. Pharm. 2005, 204:57-68.
21. Puthaviriyakorn V., Siriviriyasomboon N., Phorachata J., Pan-ox W., Sasaki T., Tanaka K. Identification of impurities and statistical classification of methamphetamine tablets (Ya-Ba) seized in Thailand. Forensic Sci. Int. 2002, 126:105-113.
22. Riddle E.L., Fleckenstein A.E., Hanson G.R. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. 2006, 8:413-418.
23. Trayner I.D., Rayner A.P., Freeman G.E., Farzaneh F. Quantitative multiwell myeloid differentiation assay using dichlorodihydrofluorescein diacetate (H2DCF-DA) or dihydrorhodamine 123 (H2R123). J. Immunol. Methods 1995, 186:275-284.
24. Trevitt J., Vallance C., Harris A., Goode T. adenosine antagonists reverse the cataleptic effects of haloperidol: implications for treatment of Parkinson's disease. Pharmacol. Biochem. Behav. 2009, 92:521-527.
25. The situation of drug abuse in Thailand, (21.11.09). http://www.healthcorners.com/2007/news/Read.php?id=12846.
26. United Nations Office on Drugs and Crime (UNODC), World Drug Report, 144, 232. , 2009. http://www.unodc.org/.